Introduction
In 2018, >63,230 estimated new cases of endometrial cancer (EC) were diagnosed and ~11,350 estimated patients died due to uterine carcinomas in the United States.
ERRα and ERα have a very high similarity in the amino acid sequence of their DBDs and ligand-binding domains (LBDs). 9, 10 However, ERRα is not activated by any known natural estrogens or physiological ligands and is, therefore, classified as an orphan nuclear receptor. 11 ERRα is expressed in a wide variety of tissues, and its high expression correlates with poor prognoses in breast, [12] [13] [14] colon 15 and prostatic cancers. 16 In our previous study, we demonstrated that ERRα overexpression was an independent marker of poor prognosis in ovarian cancer. 17 In EC, we found a positive correlation between ERRα mRNA expression and the International Federation of Gynecology and Obstetrics (FIGO) stage of myometrial invasion. 18 Furthermore, ERRα overexpression inhibited cell proliferation in ERα-responsive Ishikawa cells, but stimulated cell proliferation in ERα-nonresponsive HEC-1A cells. 19 These findings indicate that the function of ERRα depends on the level of ERRα expression as well as the function of ERα. Thus, ERRα may be a potential target for endocrine therapy of hormone-related cancers.
The synthetic molecule XCT790 is an ERRα-specific ligand and acts as an antagonist. 20 Recent studies have reported the anticancer effect of XCT790 in breast cancer through ERRα targeting via different mechanisms. 14 It is interesting that ERRα activity was shown to be elevated in tumors that are either human epidermal growth factor receptor-2 (HER2)-positive or ER-negative or those that contain P53 mutations. 21, 22 Moreover, studies showed that XCT790 was efficacious in both ERα-positive and ERα-negative breast cancer cells. 23, 24 XCT790 may be used as an exogenous agent to downregulate ERRα in EC cells. Small interfering RNA (siRNA) -a symmetric or asymmetric double-stranded RNA measuring ~20 bp -have long been used as a molecular tool to regulate the expression of the gene of interest in basic research. 25 siRNAs are currently used as biotherapeutics to silence disease-causing genes, and siRNA-mediated gene therapy is a promising strategy for transient inhibition of the expression of genes involved in the development of breast cancer. 26 Given its significant inhibitory and silencing effect on target genes, siRNA has become an invaluable tool for the downregulation of ERRα in endometrial carcinoma cells. Endocrine therapy for the treatment of EC may not be as effective as in breast cancer. Therefore, we aimed to demonstrate a novel endocrine therapy strategy by endogenous and exogenous downregulation of ERRα in endometrial carcinoma cells.
Materials and methods
Relative real-time quantitative polymerase chain reaction analysis Total RNA was extracted by the TRIzol reagent (Thermo Fisher, Los Angeles, CA, USA). Briefly, 1 µg DNase I-treated RNA samples was reverse transcribed to complementary DNA (cDNA) using a reverse transcription kit (Promega, Madison, WI, USA). The polymerase chain reaction (PCR) primer sets used were as follows: ERRα sense 5′-ACC GAG AGA TTG TGG TCA CCA-3′, anti-sense 5′-CAT CCA CAC GCT CTG CAG TACT-3′ (101 bp); glyceraldehyde 3-phosphate dehydrogenase (GADPH, control) sense 5′-GCA CCG TCA AGG CTG AGA AC-3′, anti-sense 5′-TGG TGA AGA CGC CAG TGGA-3′ (138 bp); and ERα sense 5′-CCA ATT ATG AGA TGG ACT GTG GGT A-3′, anti-sense 5′-CTT GGG AAT GGT GCA GTG TAA TCT A-3′ (99 bp). The PCR products were electrophorized on 2% agarose gel and stained with ethidium bromide. The relative level of ERRα mRNA expression was quantified by the image-intensity ratio of the target gene mRNA against GAPDH mRNA. The target gene mRNA level was quantified using the comparative method (2 −ΔΔCT method) and normalized to GAPDH expression. 14 or DMSO (control) for 24 or 48 h in this study.
Western blot analysis

lentivirus-mediated siRna construction and infection
A lentivirus-mediated siRNA named siRNA-ERRα was purchased from Genechem (Shanghai, People's Republic of China), whose specificity and knockdown effect had already been confirmed and guaranteed by the manufacturers. The siRNA target sequence selected in the ERRa gene (ESRA; GenBank accession NM_001282451.1) was as follows: siRNA-ERRα GAG CGA GAG GAG TAT GTT CTA. Stem-loop oligonucleotides were synthesized and cloned into a lentivirus-based vector carrying the green fluorescent protein (GFP) gene (GV115; Genechem). A universal sequence (PSC-NC: TTC TCC GAA CGT GTC ACG T) -NC -was used as a negative control for RNA interference, whereas cells without treatment were used as a blank. Lentivirus particles were prepared as described previously for a siRNA target sequence. The lentiviral vector constructs carrying siRNA-ERRα and NC were used to infect four EC cells at multiplicities of infection (MOI) of 100. After 72 h of infection, GFP expression was detected to calculate the infection efficiency. Cells were harvested when the infection efficiency was ≥90%. 
Apoptosis analysis via flow cytometry
For flow cytometric analysis, all cells with XCT790 treatment or siRNA treatment were seeded into six-well plates. When the cells reached 80% confluence, EDTA-free trypsin was added, and the cells were harvested. After centrifugation, cell pellets were washed twice with pre-cooled PBS. Cells were resuspended in a buffer at 10 6 cells/mL. Cells were stained with the Annexin-V-FLUOS or 7-AAD staining kit (BD, New York, NY, USA) according to the manufacturer's instructions. The proportions of apoptotic cells were measured using a FACS Canto II flow cytometer (BD) and analyzed with Diva software (BD). All experiments were conducted in triplicate.
Protein/Dna array analysis
The protein/DNA array analysis was conducted by KangChen Bio-tech Inc. (Shanghai, People's Republic of China). The array analysis procedure was undertaken according to the manufacturer's instructions. Briefly, 10 6 /mL endometrial cancer cells were seeded in 25 cm 2 cell-culture flasks (Corning, Lowell, CA, USA). Nuclear proteins were extracted using an NE-PER Nuclear Protein Extraction Kit (Pierce, Rockford, IL, USA) and quantified with a BCA protein assay kit (Beyotime, Haimen, People's Republic of China). Biotin-labeled DNA-binding probes were mixed with nuclear extract to form DNA/protein complexes, which were then passed through spin columns to remove unbound probes. The eluted bound probes were hybridized to a membrane which contained an array of 345 transcription factor (TF) consensus binding sequences (Spin Column version, Panomics, Freemont, CA, USA). After being washed, the DNA/protein array was incubated 
statistical analysis
All values were reported as mean±SD of three independent experiments, otherwise specified. An independent sample t-test and analysis of variance (ANOVA) were used to compare the parametric data using SPSS 19.0 software. A value of P<0.05 was considered statistically significant. .0687) and AN3-CA (0.984±0.0521) was significantly higher than that in HEC-1A (0.115±0.0468) (P<0.05). Moreover, negative ERa expression was observed in HEC-1B ( Figure 1C ). In line with the previous reports, our result confirmed that ERa expression was positive in RL-952 and AN3-CA cells, whereas it was weak in HEC-1A and negative in HEC-1B cells. 28 The ratio of ERa/ERRa was ~10.00-fold and 8.47-fold in RL-952 and AN3-CA, respectively, whereas it was significantly lower in HEC-1A (~3.75-fold) and HEC-1B (~0) cells ( Figure 1D ). Although the inhibitory effect of ERRa expression treated with 10 µM XCT790 for 48 h was better than that treated for 24 h, the suitable time was still 24 h in consideration of the cell quantity declining sharply after 48 h. A sharp reduction in cell quantity would influence the content of available total RNA and protein directly, which would increase the difficulty of the experiment. Above all, the inhibitory effect of ERRa expression treated with 10 µM XCT790 for 24 h was sufficiently obvious. A similar result was observed for ERRα protein expression when RL-952 ( Figure 3B ), AN3-CA ( Figure 3C ), HEC-1A ( Figure 3D ), and HEC-1B ( Figure 3E ) were treated with 10 µM XCT790 for 24 h. In line with previous reports, XCT790 failed to exert any effect on ERa expression in all EC cells at both time points ( Figure 3A ). 
Results
expression of eRRα and eRα in different eC cells
XCT790 treatment downregulated the expression of eRRα but not of eRα
XCT790 inhibited cell proliferation
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Endocrine therapy targeting ERRα in endometrial carcinoma cells Figure 4A ). Similar results were observed for ERRα protein expression in RL-52 ( Figure 4B ), AN3-CA ( Figure 4C ), HEC-1A ( Figure 4D ), and HEC-1B ( Figure 4E ). Figure 4F ).
Cell proliferation inhibition induced by siRna
Change in cell apoptosis following treatment with XCT790 and siRna
We examined apoptosis in RL-952, AN3-CA, HEC-1A, and HEC-1B EC cells treated with 10 µM XCT790 for 24 h. The apoptosis ratios of the treated cells as compared with the DMSO and blank groups were as follows: RL-952 -69.61%±5.506% vs 9.452%±1.202% and 10.21%±1.675% ( Figure 5A ), AN3-CA -77.55%±7.182% vs 11.55%±4.596% and 9.135%±2.241% ( Figure 5B ), HEC-1A -24.43%±6.564% vs 5.233%±1.839% and 6.321%±2.042% ( Figure 5C ), and HEC-1B -25.52%±3.674% vs 8.664%±1.474% and 10.01%±2.067% ( Figure 5D ). The apoptosis ratios for RL-952 and AN3-CA were noticeably higher than those in HEC-1A and HEC-1B (P<0.05). Furthermore, we examined apoptosis in the EC cells following siRNA treatment for 48 h when the fluorescence intensity of GFP was higher than 90%. The results showed that the apoptosis ratios of the four EC cells, as compared with the NC and blank groups, were as follows: RL-952 -17.52%±1.056% vs 2.814%±1.026% and 0.2031%±0.0652% ( Figure 6A ), AN3-CA-19.43%±1.613% vs 3.272%±1.692% and 3.265%±1.582% ( Figure 6B ), HEC-1A -25.51%±2.949% vs 4.031%±1.219% and 4.127%±1.608% ( Figure 6C ), and HEC-1B -27.87%±5.877% vs 5.173%±1.635% and 2.434%±0.5712% ( Figure 6D ). The apoptosis ratios for RL-952 and AN3-CA were noticeably lower than those for HEC-1A and HEC-1B (P<0.05). Figure 7B ). In general, three TFs analyzed by protein/DNA array were found to be at least 2-fold higher, whereas 17 TFs were at least 2-fold lower in KD group cells as compared to NC group cells ( Figure 7C ; Table 1 ). According to the results, there were four TFs whose P-values were below 0.05 including three upregulated TFs and one downregulated TF. Transcription factor EB (TFEB) was the only downregulated TF induced by ERRα knockdown that was related to the mTOR pathway and affected ERRα via the peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α). Moreover, the organic cation transporter 3/4 (Oct3/4) was an upregulated TF which participated in the Wnt pathway by combining with β-catenin (β-cat), and inversely regulated T-cell factor/lymphoid enhancer factor (TCF/LEF). Hepatic nuclear factor 4 (HNF-4) could modulate PGC-1α to indirectly affect ERRα ( Figure 7D ).
Discussion
The development of EC is a complex process involving multiple factors and stages. This process is mediated via different 29 Yang et al reported the regulatory effect of ERRα on the human lactoferrin gene promoter that is mediated via ERα in the EC cell line RL-952. 30 This was the first study to describe the potential role of ERRα in EC cells in vitro. In subsequent studies, Gao et al compared the in vivo expression of ERα and ERRα in human endometrial carcinoma and the normal endometrial tissue. 18 ERRα may be an indicator of poor prognoses in EC, similarly to that observed in breast, [12] [13] [14] ovarian, 17 colon, 15 and prostatic cancers. 16 The upregulation of ERRα may be related to tumor growth and progression in ECs. 31 Thus, ERRα may be a candidate prognostic factor and potential target for the treatment of EC with specific pathological types. 31 Although recent studies have improved our understanding of the role of orphan nuclear receptors in cancer, the function of ERRα remains unknown. It is well known that ERα and ERβ are inactive in the absence of hormonal signals, whereas ERRα displays a constitutive transcriptional activity as a repressor and activator. 29 Previous studies have reported extensive cross talk between ERRα and ERα. [17] [18] [19] In our previous work, the cross talk between ERRα and ERα at the transcription level was confirmed by using stable transfection experiments.
18 ERRα overexpression repressed the mRNA level of ERα but not of ERβ. However, the mechanism involved in this adverse regulation is unclear. Moreover, ERRα overexpression was associated with a proliferative mechanism in ERα-nonresponsive EC cells in HEC-1A but not in ERα-positive Ishikawa cells. 18 Therefore, the regulation of ERRα expression by estrogen and estrogenic response Figure 6 Downregulation of eRRα by siRna induces cell apoptosis. The apoptosis rates of four endometrial cancer cells Rl-952 (A), an3-Ca (B), heC-1a (C), and heC-1B (D) infected with siRna targeted on eRRα (siRna-eRRα) were analyzed by flow cytometry using an Annexin-V 7AAD Kit. Untreated EC cells were designated as the blank group, the cells infected with nonspecific siRNA as the negative control (NC) group, and the cells infected with siRNA-ERRα for 72 h as the KD group. Compared to the blank or nC group, the downregulation of eRRα by infection with siRna-eRRα led to a significant increase in cellular apoptosis. All experiments were conducted in triplicate. *Significant differences (P<0.05) are indicated. Abbreviation: KD, knockdown. 14 XCT790 is thought to downregulate the expression of the ERRα gene by inducing an actively repressive conformation. 32 We found that XCT790 inhibited the expression of ERRα not only in the ERα-negative and/or ERα-nonresponsive EC cells HEC-1A and HEC-1B, but also in the ERα-positive and -responsive EC cell lines RL-952 and AN3-CA. XCT790 treatment resulted in the inhibition of cellular proliferation via ERRα downregulation in all four cell lines. These results are in agreement with those reported by Bianco et al, 33 wherein XCT790 acted as an ERRα-specific antagonist and reduced cell proliferation in several tumor cell lines. In addition, the siRNA against ERRα decreased the expression of ERRα, inhibited cell proliferation, and induced cellular apoptosis in all EC cells.
The role of ERRα is entirely distinct between ERα-responsive and ERα-nonresponsive EC cells. The classic estrogen-ER signaling pathway is thought to be the most important factor that results in hormone-dependent endometrial carcinoma. In the presence of estradiol (E2), the estrogen-ER complex may directly or indirectly inhibit the expression of ERRα at transcriptional and/or translational level in ERα-responsive cells. This may partly explain the induction of hyperplasia and tumorigenesis of the endometrium with long-term estrogenic stimulation. 34, 35 However, the ERRα-mediated pathway may play an important role in ERα-independent endometrial carcinoma. ERRα may induce constitutive transactivation of estrogen-responsive genes, leading to an estrogenic effect. Therefore, we propose 
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Endocrine therapy targeting ERRα in endometrial carcinoma cells that the transformation of ERRα from the repressor to the activator may be key for the transformation of hormonedependent type 1 endometrial carcinoma to hormoneindependent type 2 endometrial carcinoma. It is interesting that XCT790 showed a stronger inhibitory effect against ERα-positive (high ERα/ERRα ratio) RL-952 and AN3-CA EC cells as compared to the ERα-negative (low ERα/ERRα ratio) HEC-1A and HEC-1B EC cells. However, the siRNA against ERRα was more effective in the ERα-negative cells than in the ERα-positive EC cells. Matsushima et al showed that ERRα silencing using endogenous siRNA resulted in an antitumor effect in ERα-independent HEC-1A and KLE EC cells but not in the ERα-dependent Ishikawa cells. 36 Thus, the mechanism of exogenous XCT790 and endogenous siRNA downregulation of ERRα expression may involve multiple pathways.
To further discuss the potential mechanism involved, a high-throughput protein/DNA array was carried out. Four TFs, including three upregulating TFs and one downregulating TF, were screened out as statistically significant. We focused on TFEB because there was a positive correlation between TFEB and ERRα in our research. TFEB was recently identified as the master transcriptional regulator of autophagy and lysosomal biogenesis. 37 TFEB can translocate to the nucleus following mitophagy induction to stimulate synthesis of new mitochondria via PGC-1α, because PGC-1α plays a role in mitochondrial biogenesis. TFEB can modulate PGC-1α and increase the mitochondrial content of cells. 38 Moreover, TFEB activity is inhibited by mTOR phosphorylation. 39 Therefore, it is obvious that TFEB was related to PGC-1α and might be involved in the mTOR signaling pathway. However, it is well known that PGC-1α was a coactivator of ERRα. 40 Previous studies have reported that PGC-1α induced the expression of ERRα and interacted physically with ERRα. 38 Therefore, we deduced that TFEB was associated with ERRα, which may be mediated by PGC-1α. On the other hand, Oct3/4 -an upregulated TF -is related to the self-renewal properties of stem cells. 41, 42 A study showed that Oct3/4 is downstream of the Wnt ligand, but upstream of the β-cat/TCF target genes. Oct3/4 expression promotes a dramatic decrease in β-cat. There is a feedback between the TCF/β-catenin and Oct3/4. 42 TCF regulates Oct3/4 expression by binding directly to the Oct3/4 promoter and inhibiting Oct3/4 expression. 43 Chang and McDonnell claimed ERRα was affected by the activity of TCF on several endogenous target genes, and the activation of β-cat-enhanced ERRα transcriptional activity. 44 All of the observations suggested that there was some relationship between ERRα and Oct3/4. Thus, we speculate that ERRα downregulation induced Oct3/4 upregulation, which may be mediated by TCF and is involved in the Wnt signaling pathway.
In general, both XCT790 and siRNA showed proliferation-inhibitory effects against ERRα and induced cell apoptosis via downregulation of ERRα expression in ERα-positive and ERα-negative EC cells. Thus, it can be suggested that ERRα-specific inhibitors or synthetic ligands may be valuable for the treatment of both ERα-positive and ERα-negative ECs. Furthermore, the TFs screened out by using protein/DNA array analysis participated in modulating the expression of ERRα directly, or indirectly via different signaling pathways. The screening and analysis of TFs further clarified the potential mechanism of EC therapy targeting of ERRα. Future in vivo studies should explore the therapeutic applications of this strategy, and the TFs screened out need to be validated.
Conclusion
ERRα is the target of EC antitumor treatment. Above all, exogenous XCT790 was more effective in ER-positive EC antitumor treatment whereas endogenous siRNA was more suitable for ER-negative EC antitumor treatment. The potential mechanism may involve the mTOR and Wnt pathways mediated by TFEB, Oct3/4, and so on.
